Lipidomics uncovers metabolic manifestations related to liver steatosis and low-grade systemic inflammation in diet-treated hereditary fructose intolerance patients

Serum lipidomic study revealed previously unknown metabolic complications of HFI-treated patients. Notably, we have found that low-grade systemic inflammation is highly prevalent in the cohort of HFI patients and correlates with early factors of cardiovascular risk. Expanding our current understanding of the metabolic consequences in HFI-treated patients will provide the best care for patients.